Proof of Concept
Proof of Concept (POC) studies play a critical role in determining whether an investigational therapy demonstrates the desired biological activity and clinical potential. CenExel partners with sponsors to efficiently evaluate safety, efficacy signals, biomarkers, and treatment response, helping advance promising therapies toward later-stage development with confidence.



Studies Conducted
Trial Participants
Active Sites
Leading Proof of Concept Research
Our Proof of Concept research programs are designed to provide sponsors with the critical data needed to make informed development decisions. By combining experienced investigators, specialized patient populations, and efficient operational execution, we help accelerate the transition from early discovery to clinical validation.
Our teams support first-in-patient and early efficacy studies across multiple therapeutic areas, utilizing advanced assessments, biomarkers, and patient-reported outcomes to evaluate treatment potential.
With access to diverse patient populations and therapeutic expertise, CenExel delivers high-quality data that supports strategic go/no-go decisions and optimizes development pathways.
Therapeutic Areas Supported in Proof of Concept Research
Our sites conduct Proof of Concept studies across a broad range of indications and disease areas.
Psychiatry
Neurology
Pain Management
Metabolic Disorders
Rare Diseases
Dermatology
Gastroenterology
Immunology
Women's Health
Sleep Disorders
Why Sponsors Choose CenExel for Proof of Concept Studies
Our Proof of Concept expertise goes beyond patient enrollment — we deliver scientific insight, rapid execution, and reliable outcomes.
01
Rapid Study Start-Up
Our experienced teams enable fast site activation and efficient study execution for time-sensitive acute pain trials.
02
Diverse Surgical Models
We support multiple surgical indications, providing flexibility and robust patient recruitment.
03
Opioid-Sparing Focus
Expertise in evaluating non-opioid and multimodal pain management strategies.
04
High Enrollment Performance
Consistent delivery of strong enrollment through targeted recruitment strategies.
Supported Trial Phases
We support acute pain clinical trials across all phases — from first-in-human studies to Phase IV post-marketing research, ensuring high-quality execution and reliable outcomes.
Active across all phases
Phase I
Phase II
Phase III
Phase IV
Our early phase capabilities include pharmacodynamic biomarker strategies, first-in-human studies, and proof-of-concept trial design — guided by Chief Scientific Officer Dr. Larry Ereshefsky, an internationally recognized KOL in CNS research with over 30 years of early phase expertise.
Proof of Concept Task Force
CenExel's Proof of Concept Task Force brings together experienced investigators, therapeutic experts, and operational leaders to support early-stage clinical development. Our teams focus on efficient study execution, rapid patient enrollment, biomarker integration, and generating meaningful clinical insights that help sponsors advance promising therapies.
Active Sites
15 Sites
Also in Pain & Inflammation
